Cargando…

The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity

NDRG1 is an oncogenic signaling disruptor that plays a key role in multiple cancers, including aggressive pancreatic tumors. Recent studies have indicated a role for NDRG1 in the inhibition of multiple tyrosine kinases, including EGFR, c-Met, HER2 and HER3, etc. The mechanism of activity of NDRG1 re...

Descripción completa

Detalles Bibliográficos
Autores principales: Chekmarev, Jason, Azad, Mahan Gholam, Richardson, Des R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465210/
https://www.ncbi.nlm.nih.gov/pubmed/34572031
http://dx.doi.org/10.3390/cells10092382
_version_ 1784572813522239488
author Chekmarev, Jason
Azad, Mahan Gholam
Richardson, Des R.
author_facet Chekmarev, Jason
Azad, Mahan Gholam
Richardson, Des R.
author_sort Chekmarev, Jason
collection PubMed
description NDRG1 is an oncogenic signaling disruptor that plays a key role in multiple cancers, including aggressive pancreatic tumors. Recent studies have indicated a role for NDRG1 in the inhibition of multiple tyrosine kinases, including EGFR, c-Met, HER2 and HER3, etc. The mechanism of activity of NDRG1 remains unclear, but to impart some of its functions, NDRG1 binds directly to key effector molecules that play roles in tumor suppression, e.g., MIG6. More recent studies indicate that NDRG1s-inducing drugs, such as novel di-2-pyridylketone thiosemicarbazones, not only inhibit tumor growth and metastasis but also fibrous desmoplasia, which leads to chemotherapeutic resistance. The Casitas B-lineage lymphoma (c-Cbl) protein may be regulated by NDRG1, and is a crucial E3 ligase that regulates various protein tyrosine and receptor tyrosine kinases, primarily via ubiquitination. The c-Cbl protein can act as a tumor suppressor by promoting the degradation of receptor tyrosine kinases. In contrast, c-Cbl can also promote tumor development by acting as a docking protein to mediate the oncogenic c-Met/Crk/JNK and PI3K/AKT pathways. This review hypothesizes that NDRG1 could inhibit the oncogenic function of c-Cbl, which may be another mechanism of its tumor-suppressive effects.
format Online
Article
Text
id pubmed-8465210
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84652102021-09-27 The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity Chekmarev, Jason Azad, Mahan Gholam Richardson, Des R. Cells Review NDRG1 is an oncogenic signaling disruptor that plays a key role in multiple cancers, including aggressive pancreatic tumors. Recent studies have indicated a role for NDRG1 in the inhibition of multiple tyrosine kinases, including EGFR, c-Met, HER2 and HER3, etc. The mechanism of activity of NDRG1 remains unclear, but to impart some of its functions, NDRG1 binds directly to key effector molecules that play roles in tumor suppression, e.g., MIG6. More recent studies indicate that NDRG1s-inducing drugs, such as novel di-2-pyridylketone thiosemicarbazones, not only inhibit tumor growth and metastasis but also fibrous desmoplasia, which leads to chemotherapeutic resistance. The Casitas B-lineage lymphoma (c-Cbl) protein may be regulated by NDRG1, and is a crucial E3 ligase that regulates various protein tyrosine and receptor tyrosine kinases, primarily via ubiquitination. The c-Cbl protein can act as a tumor suppressor by promoting the degradation of receptor tyrosine kinases. In contrast, c-Cbl can also promote tumor development by acting as a docking protein to mediate the oncogenic c-Met/Crk/JNK and PI3K/AKT pathways. This review hypothesizes that NDRG1 could inhibit the oncogenic function of c-Cbl, which may be another mechanism of its tumor-suppressive effects. MDPI 2021-09-10 /pmc/articles/PMC8465210/ /pubmed/34572031 http://dx.doi.org/10.3390/cells10092382 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chekmarev, Jason
Azad, Mahan Gholam
Richardson, Des R.
The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity
title The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity
title_full The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity
title_fullStr The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity
title_full_unstemmed The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity
title_short The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity
title_sort oncogenic signaling disruptor, ndrg1: molecular and cellular mechanisms of activity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465210/
https://www.ncbi.nlm.nih.gov/pubmed/34572031
http://dx.doi.org/10.3390/cells10092382
work_keys_str_mv AT chekmarevjason theoncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity
AT azadmahangholam theoncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity
AT richardsondesr theoncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity
AT chekmarevjason oncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity
AT azadmahangholam oncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity
AT richardsondesr oncogenicsignalingdisruptorndrg1molecularandcellularmechanismsofactivity